Get the Stockscreener App
2.72
4.56%
-0.13
After Hours:
2.70
-0.02
-0.74%
Lisata Therapeutics Inc stock is traded at $2.72, with a volume of 46,320.
It is down -4.56% in the last 24 hours and down -8.42% over the past month.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
See More
Previous Close:
$2.85
Open:
$2.7199
24h Volume:
46,320
Relative Volume:
3.67
Market Cap:
$23.18M
Revenue:
-
Net Income/Loss:
$-21.07M
P/E Ratio:
-0.2745
EPS:
-9.9082
Net Cash Flow:
$-19.96M
1W Performance:
-6.21%
1M Performance:
-8.42%
6M Performance:
-1.81%
1Y Performance:
+17.75%
1-Day Range:
$2.70
$2.80
1-Week Range:
$2.70
$2.94
52-Week Range:
$2.05
$3.83
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LSTA | 2.72 | 23.18M | 0 | -21.07M | -19.96M | -9.9082 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborationsICYMI - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors Australia
Earnings call: Lisata Therapeutics reports on Q3 progress and trials - Investing.com
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2024 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost Management Success - GuruFocus.com
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... By GuruFocus - Investing.com Canada
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... - Yahoo Finance
Lisata Therapeutics Reports Q3 2024 Financial Results - TipRanks
Lisata Therapeutics Inc Reports Q3 2024 EPS of $0.59 and Net Los - GuruFocus.com
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025 - Proactive Investors USA
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LSTALisata Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Lisata and ValoTx announce melanoma research collaboration - Investing.com
Lisata and ValoTx announce melanoma research collaboration By Investing.com - Investing.com UK
Lisata Therapeutics forms partnership for preclinical cancer immunotherapy study - Proactive Investors USA
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration - The Manila Times
Lisata, Valo Therapeutics Partner on Novel Melanoma Treatment Study | Key Research Collab | LSTA Stock News - StockTitan
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 - The Manila Times
Lisata Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Lisata Therapeutics to Report Q3 2024 Results: Clinical-Stage Cancer Drug Updates | LSTA Stock News - StockTitan
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapyICYMI - Proactive Investors Australia
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know - MSN
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive Investors UK
Lisata announces preclinical research agreement to study certepetide with bevacizumab for endometriosis - BioWorld Online
Lisata Therapeutics Announces Sponsored Preclinical - GlobeNewswire
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis - Proactive Investors USA
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis - GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events - The Manila Times
Lisata Therapeutics reiterates stock target, buy rating amid trial update - Investing.com India
Troy Wichterman Sells 611 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock - Defense World
Biolife Solutions exec sells over $77k in company stock - Investing.com India
Bilibili Inc. (NASDAQ:BILI) Short Interest Update - Defense World
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Down 7.1% in August - Defense World
Lisata Therapeutics reiterates stock target, buy rating amid trial update By Investing.com - Investing.com Canada
Market cap of Bilibili Inc ADR [BILI] reaches 4.87B – now what? - The DBT News
BLFS (Biolife Solutions Inc) may reap gains as insiders became active recently - Knox Daily
Daiwa Securities Group Inc. Has $71,000 Stock Position in Bilibili Inc. (NASDAQ:BILI) - Defense World
Short Interest in Bilibili Inc. (NASDAQ:BILI) Drops By 8.3% - MarketBeat
FDA Approves Ebglyss for Treatment of Moderate to Severe Atopic Dermatitis - Managed Healthcare Executive
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update - MarketBeat
Lisata Therapeutics Announces First Patient Treated in the - GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial - StockTitan
Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial - Proactive financial news
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children - The Dermatologist
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis - Patient Care Online
Ebglyss Approved for Moderate to Severe Atopic Dermatitis - Monthly Prescribing Reference
FDA Approves Lebrikizumab for Atopic Dermatitis - Medscape
Lilly gains FDA approval for lebrikizumab for atopic dermatitis - Seeking Alpha
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis - Investors | Eli Lilly and Company
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):